DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
AVTR logo

Avantor, Inc. Stock Price

NYSE:AVTR Community·US$10.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 19 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

AVTR Share Price Performance

US$14.88
1.87 (14.37%)
​
US$14.56
Fair Value
US$14.88
1.87 (14.37%)
2.2% overvalued intrinsic discount
US$14.56
Fair Value
Price US$14.88
AnalystConsensusTarget US$14.56
AnalystLowTarget US$12.00
AnalystHighTarget US$17.94
Fri, 14 Aug 26
Fair ValueUS$14.56
Share Pricen/a

AVTR Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$14.56 2.2% overvalued intrinsic discount

AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$12 24.0% overvalued intrinsic discount

Digital Transformation And Rising Costs Will Undermine Lab Chemicals Sector

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$17.94 17.1% undervalued intrinsic discount

Secular Trends And Cell Therapies Will Expand Markets Despite Risks

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AVTR logo
Avantor
24.0% overvalued intrinsic discount

Digital Transformation And Rising Costs Will Undermine Lab Chemicals Sector

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
AVTR logo
Avantor
2.2% overvalued intrinsic discount

AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 14 Aug
Read Narrative
AVTR logo
Avantor
17.1% undervalued intrinsic discount

Secular Trends And Cell Therapies Will Expand Markets Despite Risks

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 30 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
AVTR logo

AVTR: Early Turnaround Progress Will Likely Struggle To Sustain Elevated Earnings Multiple

Fair Value: US$12 24.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
AVTR logo

AVTR: Turnaround Progress And Sector Tailwinds Will Likely Define Next Phase

Fair Value: US$14.56 2.2% overvalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
AVTR logo

AVTR: Turnaround Execution And Sector Recovery Will Support Future Repricing

Fair Value: US$17.94 17.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Good value with moderate growth potential.

1 Risk
3 Rewards
View Full Analysis

Avantor, Inc. Key Details

US$6.6b

Revenue

US$4.5b

Cost of Revenue

US$2.1b

Gross Profit

US$2.7b

Other Expenses

-US$578.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.85
31.83%
-8.81%
65.2%
View Full Analysis

About AVTR

Founded
1904
Employees
13500
CEO
Emmanuel Ligner
WebsiteView website
www.avantorsciences.com

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Recent AVTR News & Updates

User avatar
Narrative Update • Sep 03

AVTR: Early Turnaround Progress Will Likely Struggle To Sustain Elevated Earnings Multiple

Analysts have lifted the fair value estimate for Avantor to $12 from $7, reflecting a series of higher Street price targets around $12 to $14 that are tied to recent Q2 earnings beats, early progress under the new CEO, and ongoing self help initiatives. Analyst Commentary Recent research updates on Avantor show a cluster of higher fair value and price targets after the Q2 earnings beat and the early phase of the new CEO's plan.
Seeking Alpha • Aug 28

Avantor: Smaller Green Shoots Of Organic Growth Returning Are Well Priced In

Summary Avantor has shown stabilization, with organic growth returning and leverage concerns receding as net debt declines. Avantor raised its full-year organic sales and adjusted earnings guidance, signaling a likely return to positive growth in H2. Margin improvement remains a key lever; every 1% margin gain could add $0.10 per share pre-tax, but topline growth is required. Shares have nearly doubled since April, reflecting improved outlook, but current valuations already price in much of the good news. Read the full article on Seeking Alpha

Recent updates

No updates

Avantor, Inc. Competitors

MRNA logo

Moderna

Symbol: NasdaqGS:MRNA
Market cap: US$54.1b
NTRA logo

Natera

Symbol: NasdaqGS:NTRA
Market cap: US$47.6b
RVMD logo

Revolution Medicines

Symbol: NasdaqGS:RVMD
Market cap: US$44.5b
TEVA logo

Teva Pharmaceutical Industries

Symbol: NYSE:TEVA
Market cap: US$42.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide